{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:56:13Z","timestamp":1790646973258,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"DOI":"10.1038\/s41366-026-02229-6","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:53:13Z","timestamp":1790599993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-0203","authenticated-orcid":false,"given":"Andreea","family":"Ciudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zimner-Rapuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-804X","authenticated-orcid":false,"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-7924","authenticated-orcid":false,"given":"Marine","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Curteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-2420","authenticated-orcid":false,"given":"Laura J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2229_CR1","first-page":"s176","volume":"22","author":"CM Apovian","year":"2016","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22:s176\u201385.","journal-title":"Am J Manag Care"},{"key":"2229_CR2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.pcl.2011.09.006","volume":"58","author":"JA Skelton","year":"2011","unstructured":"Skelton JA, Irby MB, Grzywacz JG, Miller G. Etiologies of obesity in children: nature and nurture. Pediatr Clin North Am. 2011;58:1333\u201354.","journal-title":"Pediatr Clin North Am"},{"key":"2229_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/10408390903372599","volume":"49","author":"EJ McAllister","year":"2009","unstructured":"McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49:868\u2013913.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2229_CR4","unstructured":"National Institute for Health and Care Excellence (NICE) Overweight and obesity management. NICE guideline [NG246]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng246 [Last accessed: July 2026]. 2025."},{"key":"2229_CR5","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.15077","volume":"25","author":"M Bl\u00fcher","year":"2023","unstructured":"Bl\u00fcher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, et al. New insights into the treatment of obesity. Diab Obes Metab. 2023;25:2058\u201372.","journal-title":"Diab Obes Metab"},{"key":"2229_CR6","unstructured":"World Health Organization (WHO) Obesity and Overweight Fact Sheet. Available at: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/obesity-and-overweight [Accessed: July 2026]. 2024."},{"key":"2229_CR7","doi-asserted-by":"crossref","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JC, Sbraccia P, Yumuk V, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024:1\u20135.","DOI":"10.1038\/s41591-024-03095-3"},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8:402\u201324.","journal-title":"Obes Facts"},{"key":"2229_CR9","unstructured":"Dietz WHBB, Bradley D, et al. A model framework that integrates community and clinical systems for the prevention and management of obesity and other chronic diseases. NAM Persp. 2017."},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192:E875\u2013e91.","journal-title":"CMAJ"},{"key":"2229_CR11","unstructured":"US Food and Drug Administration (FDA). Wegovy Label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf [Last accessed: July 2026]. 2023."},{"key":"2229_CR12","unstructured":"European Medicines Agency (EMA). Wegovy Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf [Last accessed: July 2026]. 2022."},{"key":"2229_CR13","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Wegovy Summary of Product Characteristics. Available from: https:\/\/products.mhra.gov.uk\/product\/?product=WEGOVY [Last accessed: July 2026]."},{"key":"2229_CR14","unstructured":"European Medicines Agency (EMA). Mounjaro Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mounjaro-epar-product-information_en.pdf [Last accessed: July 2026]. 2022."},{"key":"2229_CR15","unstructured":"US Food and Drug Administration. Zepbound Label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf [Last accessed: July 2026]. 2023."},{"key":"2229_CR16","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Mounjaro Summary of Product Characteristics. Available from: https:\/\/products.mhra.gov.uk\/product\/?product=MOUNJARO&page=3 [Last accessed: July 2026]. 2024."},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"2229_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"2229_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26\u201336.","journal-title":"N Engl J Med"},{"key":"2229_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102777","volume":"75","author":"M Anson","year":"2024","unstructured":"Anson M, Henney AE, Broadwell N, Zhao SS, Ibarburu GH, Lip GYH, et al. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real-world evidence from an international retrospective cohort study. eClinicalMedicine. 2024;75:102777.","journal-title":"eClinicalMedicine"},{"key":"2229_CR21","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/dom.15148","volume":"25","author":"CW le Roux","year":"2023","unstructured":"le Roux CW, Hankosky ER, Wang D, Malik R, Yu M, Hickey A, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison. Diab, Obes Metab. 2023;25:2626\u201333.","journal-title":"Diab, Obes Metab"},{"key":"2229_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13543","volume":"24","author":"OS Alkhezi","year":"2023","unstructured":"Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023;24:e13543.","journal-title":"Obes Rev"},{"key":"2229_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"XH Pan","year":"2024","unstructured":"Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity. 2024;32:840\u201356.","journal-title":"Obesity"},{"key":"2229_CR24","unstructured":"RCore Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2023."},{"key":"2229_CR25","unstructured":"European Medicines Agency (EMA). ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf [Accessed: July 2026]. 2020."},{"key":"2229_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"2229_CR27","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades A. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment. Report by the Decision Support Unit. 2011."},{"key":"2229_CR28","unstructured":"Health Technology Assessment Coordination Group (HTA CG). Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. Available from: https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf [Last accessed: July 2026]. 2024."},{"key":"2229_CR29","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). Available from: https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf [Last accessed: July 2026]. 2016."},{"key":"2229_CR30","unstructured":"National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (GID-TA10765). Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10765\/. [Last accessed July 2026]. 2022."},{"key":"2229_CR31","unstructured":"Eli Lilly. SURMOUNT-1 Protocol. Efficacy and safety of tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight with weight- related comorbidities: a randomized, double-blind, placebo-controlled trial (SURMOUNT-1) 2022."},{"key":"2229_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640\u20135.","journal-title":"Circulation"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02229-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:56Z","timestamp":1790643896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":32,"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02229-6","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC: Honoraria from AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk; Member of the DMC of Boehringer Ingelheim clinical trials-SYNCRONIZE program; EJ, SZR, GKD, MB, LF, HS: Employee and shareholder of Eli Lilly and Company; TC, LJC: Employees of Costello Medical, which received payment from Eli Lilly and Company for analytical services for this study; JFB: Received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Gilead, GSK, IQVIA, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Takeda.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}